A dearth of truth in medical advertising is probably our greatest public health threat. With consumers bombarded by spurious claims, our agencies need to be proactive, not reactive in protecting the public.
Commissioner Scott Gottlieb
The U.S. Court of Appeals just delivered another blow to a rather-clever-but-cunning play by Allergan, the pharmaceutical giant, to game the patent system.
Can the FDA's tactics – to impact the current opioid problem – also predict its successor? The goal is to head off escalation before problems are crises, and the move is a departure from the status-quo, reactive nature of prior policies.